sexta-feira, 13 de novembro de 2026
PesquisarExplore
Via News Knowledge File

JPMorgan Chase & Co.

organization80% conf.·synced Nov 13, 2026

Financial institution partnering with QuantiNUM on cybersecurity and encryption applications

60
sourced metrics
726
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap
911279391370USD
Nov 12, 2026reference only
Stock Return Ytd
5.3%
Nov 12, 2026reference only
Price 52 Week High
365.18USD
Nov 12, 2026reference only
Price 52 Week Low
282.84USD
Nov 12, 2026reference only
Stock Price
342.82USD
Nov 12, 2026reference only
Eps
7.7USD_per_share
Jun 30, 2026reference only
Shares Outstanding
2658186195.0shares
Jun 30, 2026reference only
Net Income
21155000000.0USD
Jun 30, 2026reference only
Total Assets
5015069000000.0USD
Jun 30, 2026reference only
Total Liabilities
4640471000000.0USD
Jun 30, 2026reference only
Stockholders Equity
374598000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
-211761000000.0USD
Mar 31, 2026reference only
Revenue
182447000000.0USD
Dec 31, 2025reference only

Stated objectives

Projected AI-related deals in leveraged finance over five years

source
target: 150 billion USD by 2030-01-01 00:00:00stated

Projected AI and data center related deals annually for five years

source
target: 300 billion USD per year by 2030-01-01 00:00:00stated

Projected annual data center securitization issuance

source
target: 30-40 billion USD stated

S&P 500 companies expected to achieve 13%-15% earnings growth over next two years

source
target: 13-15 percent by 2027-01-01 00:00:00stated

S&P 500 companies expected to achieve 13-15% earnings growth over next two years

source
target: 13-15% by 2026-12-31 00:00:00stated

JPMorgan forecasts S&P 500 reaching 7,500 by end of 2026, potentially above 8,000 with continued Fed rate cuts

source
target: 7500-8000 by 2026-12-31 00:00:00stated

JPMorgan forecasts Brent crude to fall to $58 per barrel in 2026

source
target: 58 USD per barrel by 2026-12-31 00:00:00stated

S&P 500 price target of 7,500 by end of 2026

source
target: 7500 by 2026-12-31 00:00:00stated

Top picks for 2026 include GE Vernova, Brookfield Renewable Partners, and Nextpower with bias toward US-based manufacturing and diversified end markets

source
by 2026-01-01 00:00:00stated

Gold price forecast to reach $5,055 per ounce by late 2026

source
target: 5055 USD per ounce by 2026-12-01 00:00:00stated

Relationship graph · 726 connections

Covered by
216
Employs
135
Competes with
83
rates
52
regulates
38
financed by
19
subsidiary of
19
Customer of
18

Where sources disagree

We surface conflicts between sources rather than hiding them.

value conflictunresolved

Both facts give JPMorgan Chase's stockholders' equity at the same point in time (2025-12-31). Stockholders' equity is a point-in-time balance, and FY 2025 and Q4 2025 both end on that date, so the periods coincide. Fact A reports 362,438,000,000 USD and Fact B reports 362 USD. The values differ by about nine orders of magnitude. Fact B is most likely a scale or unit error (362 could be a truncated 362 billion), but it is labelled USD, so as stated the two facts cannot both be true.

value conflictunresolved

Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.

value conflictunresolved

Both facts represent the same entity (JPMorgan Chase & Co.), same attribute (EPS), and same observation date (2025-12-31), which aligns with FY 2025 year-end reporting. Fact A explicitly states FY 2025 with EPS of 20.02 USD/share. Fact B has an unspecified fiscal period (N/A) but reports 4.63 USD, a significantly different value (4.3x lower). Given identical observation dates and the same metric, both facts appear intended to represent FY 2025 annual EPS. The conflicting values (20.02 vs 4.63) constitute a direct contradiction. The N/A period in Fact B suggests incomplete or corrupted metadata rather than legitimate time-period variation.

value conflictunresolved

Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com